|
**Overview**: Mycoplasma Pneumoniae Antibodies Panel**Introduction**: The Mycoplasma Pneumoniae Antibodies Panel is a diagnostic tool designed to screen for Mycoplasma pneumoniae infection using serum samples. In India, Mycoplasma pneumoniae causes ~10-30 percent of community-acquired pneumonia, especially in school-age children and young adults, with outbreaks in crowded settings. High morbidity from under-testing in rural/low-SES patients with atypical pneumonia, dry cough, or extrapulmonary manifestations (hemolysis, rash), limited serology labs, delayed macrolide therapy leading to prolonged illness or complications. Per microbiology practices aligned with ICMR and Indian Academy of Pediatrics guidelines, the test employs immunoassay for Mycoplasma IgG and IgM over 1-2 days with high specificity, valuable for acute diagnosis (IgM rise) or past exposure (IgG). This diagnostic falls under infection screening and targets patients with persistent cough or pneumonia unresponsive to beta-lactams, addressing accurate detection to guide azithromycin or doxycycline. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise atypical pathogen identification and reducing pneumonia burden. Its serum-based approach ensures reliable antibody detection.**Other Names**: Mycoplasma Ab Pnl.**FDA Status**: FDA approved, CLIA certified for microbiology/immunology, compliant with 2025 standards.**Historical Milestone**: IgM/IgG serology standard; in India, used in respiratory clinics.**Purpose**: The test assesses 2 parameters including Mycoplasma IgG to guide infection screening, detect acute/past exposure, inform antibiotics.**Test Parameters**: 1. Mycoplasma IgG, 2. Mycoplasma IgM.**Pretest Condition**: No fasting required; patients should report persistent cough or pneumonia.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cough duration, fever, extrapulmonary symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated Mycoplasma including complications, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or early sampling can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive IgM indicates acute infection; IgG positive past exposure, necessitating specialist input.**Specialist Consultation**: Pulmonologists or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: PCR, cold agglutinins for confirmation.**Test Limitations**: Cross-reactivity possible; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, Respiratory Studies India 2023. |
